2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. Issue 1 (1st January 2022)

• Record Type: Journal Article
• Authors: Pacini, Furio; Fuhrer, Dagmar; Elisei, Rossella; Handkiewicz-Junak, Daria; Leboulleux, Sophie; Luster, Markus; Schlumberger, Martin; Smit, Johannes W
• Is Part Of: European thyroid journal. Volume 11:Issue 1(2022)
• Publication Date: 2022-01-01
• Subjects: differentiated thyroid cancer -- radioiodine -- treatment -- indications; Thyroid gland -- Diseases -- Periodicals; Thyroid Diseases -- Periodicals; 612.44
• DOI: 10.1530/ETJ-21-0046
• Languages: English
• ISSNs: 2235-0640

Abstract

Abstract : Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients' risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.